Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable
Maravai LifeSciences Holdings, Inc. has been upgraded to a Buy rating due to improved earnings and operational restructuring. The company has raised its revenue guidance for 2026 to between $205 million and $215 million, along with an adjusted EBITDA forecast of $30 million to $32 million. These developments suggest a positive outlook for the company's future performance.
- ▪Maravai LifeSciences has been upgraded to a Buy rating.
- ▪The company raised its 2026 revenue guidance to $205–$215 million.
- ▪Adjusted EBITDA is projected to be between $30 million and $32 million.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906023-maravai-lifesciences-better-earnings-drive-gains-that-ought-to-be-sustainable"},"author":{"@type":"Person","name":"Edmund…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
